ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Third, we evaluate our method based on the clinical success of Gleevec, a drug therapy of chronic myeloid leukemia, that specifically inhibits BCR-ABL, but not c-Src which is a structurally similar kinase (Deininger et al., 2005).